KCT0007375
Active, not recruiting
未知
The Effect of Intravitreal Aflibercept for Neovascular membrane, Pigment Epithelial Detachment and/or Subretinal Fluid Secondary to Type 1 Choroidal Neovascularization: Quantitative analysis based on OCT and OCT Angiography
Kyung Hee University Hospital0 sites40 target enrollmentTBD
ConditionsDiseases of the eye and adnexa
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Diseases of the eye and adnexa
- Sponsor
- Kyung Hee University Hospital
- Enrollment
- 40
- Status
- Active, not recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Active choroidal neovascularization confirmed by optical coherence tomography angiography or fluorescein angiography and indocyanine green angiography
- •\- When the subretinal fluid accompanied by irregular elevation of the retinal pigment epithelium is confirmed by optical coherence tomography
- •\- In cases where choroidal neovascularization is observed in optical coherence tomography angiography or fluorescein angiography and indocyanine green angiography
- •2\. Male or female patients over 50 years of age who have signed the informed consent form
- •3\. In the absence of active ocular or systemic disease
- •4\. Patients who understand the process of this clinical trial, are cooperative, and are judged to be able to participate by the end of the clinical trial
Exclusion Criteria
- •1\. Pregnant or lactating women
- •2\. Patients participating in other clinical trials
- •3\. If patient have received anti\-vascular endothelial growth factor treatment within the last 90 days
- •4\. If patient have received photodynamic therapy 3 times or more or within the last 90 days
- •5\. Clinically prominent diabetic retinopathy or diabetic macular edema
- •6\. Clinically significant scar or atrophy of the fovea
- •7\. Active Intraocular Inflammation or Infection
- •8\. In case of hypersensitivity to Afilbercept and other ingredients in Eylea
- •9\. History of intravitreal triamcinolone injection treatment within the last 3 months
- •10\. History of intravitreal dexamethasone injection treatment within the last 6 months
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 4
The study of Intravitreal aflibercept with treat and extend regimen for macular edema with branch retinal vein occlusion (BRVO)Branch retinal vein occlusionJPRN-UMIN000023200Department of Ophthalmology, Akita University50
Completed
Not Applicable
Efficacy evaluation of intravitreal aflibercept for polypoidal choroidal vasculopathyJPRN-UMIN000010461Yokohama City University Medical Center30
Completed
Phase 3
The efficacy of intravitreal aflibercept given in a ‘treat and extend’ regime in the treatment of cystoid macular oedema secondary to central retinal vein occlusion.central retinal vein occlusion (CRVO).cystoid macular oedemaEye - Diseases / disorders of the eyeACTRN12615000417583Centre for Eye Research Australia20
Completed
Not Applicable
Effect of Intravitreal Aflibercept Injection on Microaneurysm in Patients with Diabetic Macular EdemaJPRN-UMIN000018315Department of Ophthalmology, Mie University30
Active, not recruiting
Phase 1
The Effect of Intravitreal Aflibercept on Ocular Perfusion – a Pilot StudyExudative AMDMedDRA version: 19.1Level: LLTClassification code 10025411Term: Macular degeneration senileSystem Organ Class: 100000004853Therapeutic area: Diseases [C] - Eye Diseases [C11]EUCTR2016-004608-78-ATKepler University Hospital, Institute of Ophthalmology